The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

USPSTF under threat of elimination, former members warn

Trump administration announces “major crackdown” on healthcare fraud

FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases

At Friends meeting, Pazdur, Woodcock lament FDA’s failure to protect the agency staff from political interference, warn of “lasting implications”

Bayer agrees to $7.25B settlement over lawsuits alleging Roundup weedkiller caused cancer

Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

Clinical Roundup

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

Phase I/II PYNNACLE trial evaluating rezatapopt shows proof of concept for p53 reactivation

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

In The Clinic
Trials & Tribulations

Why infection and immunity matter for Florida’s cancer patients

FreeTrials & Tribulations
News Analysis
Health Equity

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account